1263187-98-9

Upstream product

• 828-25-1 (+/-)-3-(4-iodophenoxy)-1,2-epoxypropane 
• 57531-37-0 2-chloro-4-nitro-1H-imidazole 
• 540-38-5 p-Iodophenol 

Downstream Products

• 1263187-99-0 2-[(4-iodophenoxy)methyl]-6-nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazole 
• 1263187-17-2 2-{[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]methyl}-6-nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazole 
• 1263187-18-3 6-nitro-2-({[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]oxy}methyl)-2,3-dihydroimidazo[2,1-b][1,3]oxazole 
• 1263187-19-4 6-nitro-2-({[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]oxy}methyl)-2,3-dihydroimidazo[2,1-b][1,3]oxazole 

Relevant academic research and scientific papers

Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis

6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazole derivatives were initially studied for tuberculosis within a backup program for the clinical trial agent pretomanid (PA-824). Phenotypic screening of representative examples against kinetoplastid diseases unexpectedly led to the identification of DNDI-VL-2098 as a potential first-in-class drug candidate for visceral leishmaniasis (VL). Additional work was then conducted to delineate its essential structural features, aiming to improve solubility and safety without compromising activity against VL. While the 4-nitroimidazole portion was specifically required, several modifications to the aryloxy side chain were well-tolerated e.g., exchange of the linking oxygen for nitrogen (or piperazine), biaryl extension, and replacement of phenyl rings by pyridine. Several less lipophilic analogues displayed improved aqueous solubility, particularly at low pH, although stability toward liver microsomes was highly variable. Upon evaluation in a mouse model of acute Leishmania donovani infection, one phenylpyridine derivative (37) stood out, providing efficacy surpassing that of the original preclinical lead.

NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES

The current invention pertains to nitroimidazooxazine and nitroimidazooxazole analogues, their methods of preparation, and uses of the compounds as treatment for Mycobacterium tuberculosis, for use as anti-tubercular drugs, for use as anti-protozoal agents with unexpectedly high potency against Trypanosoma cruzi or Leishmania donovani, and for the treatment of other microbial infections.